Hypofrontality in schizophrenic patients and its relevance for the choice of antipsychotic medication: An event-related potential study

World Journal of Biological Psychiatry

Volumn 13, Issue 3, 2012, Pages 188-199

  Ehlis, Ann Christine ^a,d,e   Pauli, Paul ^a   Herrmann, Martin J ^a   Plichta, Michael M ^b   Zielasek, Jürgen ^c   Pfuhlmann, Bruno ^a   Stöber, Gerald ^a   Ringel, Thomas ^a   Jabs, Burkhard ^d   Fallgatter, Andreas J ^a,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c Department of Orthopedic Surgery   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

anterior cingulate cortex (ACC); antipsychotics; prefrontal cortex; response inhibition; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; BIPERIDEN; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LITHIUM; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

ADULT; ARTICLE; BRAIN METABOLISM; COGNITION; EVENT RELATED POTENTIAL; FEMALE; FOLLOW UP; FRONTAL CORTEX; FRONTAL LOBE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBIOLOGY; NEUROPHYSIOLOGY; QUALITY OF LIFE; SCHIZOPHRENIA; SELF REPORT; SYMPTOM; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BRAIN MAPPING; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; FOLLOW-UP STUDIES; FRONTAL LOBE; GYRUS CINGULI; HUMANS; INHIBITION (PSYCHOLOGY); MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 84858138928     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.566354     Document Type: Article

References (63)

1. Abbruzzese M, Ferri S, Scarone S. 1997. The selective breakdown of frontal functions in patients with obsessive-compulsive disorder and in patients with schizophrenia: a double dissociation experimental fi nding. Neuropsychologia 35: 907-912. (Pubitemid 27263234)
2. Abi-Dargham A, Laruelle M. 2005. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20: 15-27. (Pubitemid 40092387)
3. Allen DN, Goldstein G, Weiner C. 2001. Differential neuropsychological patterns of frontal-and temporal-lobe dysfunction in patients with schizophrenia. Schizophr Res 48: 7-15. (Pubitemid 32241179)
4. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL et al. 1997. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349: 1730-1734. (Pubitemid 27252672)
5. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. 1997. Differential relationships between positive and negative symptoms and neuropsychological defi cits in schizophrenia. Schizophr Res 25: 1-10. (Pubitemid 27239625)
6. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Tost H, Henn FA. 2002. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur Neuropsychopharmacol 12: 145-152. (Pubitemid 34168480)
7. Carter CS, MacDonald AW, 3rd, Ross LL, Stenger VA. 2001. Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study. Am J Psychiatry 158: 1423-1428. (Pubitemid 32847240)
8. Coull JT, Frith CD, Dolan RJ. 1999. Dissociating neuromodulatory effects of diazepam on episodic memory encoding and executive function. Psychopharmacology (Berlin) 145: 213-222. (Pubitemid 29362020)
9. de Bruijn ERA, Hulstijn W, Verkes RJ, Ruigt GSF, Sabbe BGC. 2004. Drug-induced stimulation and suppression of action monitoring in healthy volunteers. Psychopharmacology (Berlin) 177: 151-160. (Pubitemid 40109925)
10. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. 2005. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25: 10831-10843. (Pubitemid 41692613)
11. Ehlis AC, Zielasek J, Herrmann MJ, Ringel T, Jacob C, Fallgatter AJ. 2005a. Benefi cial effect of atypical antipsychotics on prefrontal brain function in acute psychotic disorders. Eur Arch Psychiatry Clin Neurosci 255: 299-307. (Pubitemid 41618801)
12. Ehlis AC, Zielasek J, Herrmann MJ, Ringel T, Jacob C, Wagener A et al. 2005b. Evidence for unaltered brain electrical topography during prefrontal response control in cycloid psychoses. Int J Psychophysiol 55: 165-178. (Pubitemid 40093098)
13. Ehlis AC, Herrmann MJ, Pauli P, Stoeber G, Pfuhlmann B, Fallgatter AJ. 2007a. Improvement of prefrontal brain function in endogenous psychoses under atypical antipsychotic treatment. Neuropsychopharmacology 32: 1669-1677. (Pubitemid 47076376)
14. Ehlis AC, Reif A, Herrmann MJ, Lesch KP, Fallgatter AJ. 2007b. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology 32: 162-170. (Pubitemid 44967794)
15. Fallgatter AJ. 2001. Electrophysiology of the prefrontal cortex in healthy controls and schizophrenic patients: a review. J Neural Transm 108: 679-694. (Pubitemid 32662412)
16. Fallgatter AJ, Brandeis D, Strik WK. 1997. A robust assessment of the NoGo-anteriorisation of P300 microstates in a cued Continuous Performance Test. Brain Topogr 9: 295-302. (Pubitemid 27331988)
17. Fallgatter AJ, Mueller TJ, Strik WK. 1999. Age-related changes in the brain electrical correlates of response control. Clin Neurophysiol 110: 833-838. (Pubitemid 29281683)
18. Fallgatter AJ, Eisenack SS, Neuhauser B, Aranda D, Scheuerpfl ug P, Herrmann MJ. 2000. Stability of late event-related potentials: topographical descriptors of motor control compared with the P300 amplitude. Brain Topogr 12: 255-261. (Pubitemid 30487669)
19. Fallgatter AJ, Aranda DR, Bartsch AJ, Herrmann MJ. 2002a. Long-term reliability of electrophysiologic response control parameters. J Clin Neurophysiol 19: 61-66. (Pubitemid 34242495)
20. Fallgatter AJ, Bartsch AJ, Herrmann MJ. 2002b. Electrophysiological measurements of anterior cingulate function. J Neural Transm 109: 977-988. (Pubitemid 34810787)
21. Fallgatter AJ, Bartsch AJ, Zielasek J, Herrmann MJ. 2003. Brain electrical dysfunction of the anterior cingulate in schizophrenic patients. Psychiatry Res 124: 37-48. (Pubitemid 37159332)
22. Friedman L, Knutson L, Shurell M, Meltzer HY. 1991. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 29: 865-877.
23. Fuchs M, Kastner J, Wagner M, Hawes S, Ebersole JS. 2002. A standardized boundary element method volume conductor model. Clin Neurophysiol 113: 702-712. (Pubitemid 34439274)
24. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE et al. 2005. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp 25: 60-69. (Pubitemid 40656193)
25. Green MF, Kern RS, Heaton RK. 2004. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72: 41-51. (Pubitemid 39452904)
26. Honer WG, Smith GN, Lapointe JS, MacEwan GW, Kopala L, Altman S. 1995. Regional cortical anatomy and clozapine response in refractory schizophrenia. Neuropsychopharmacology 13: 85-87.
27. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. 1999. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 96: 13432-13437.
28. Ichikawa J, Meltzer HY. 1999. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 90-98.
29. Ichikawa J, Dai J, Meltzer HY. 2001. DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res 907: 151-155. (Pubitemid 32595524)
30. Ichikawa J, Chung Y-C, Dai J, Meltzer HY. 2005. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Res 1052: 56-62. (Pubitemid 41116287)
31. Ingvar DH, Franzen G. 1974. Distribution of cerebral activity in chronic schizophrenia. Lancet 2: 1484-1486.
32. Jakab RL, Goldman-Rakic PS. 1998. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95: 735-740.
33. Jurcak V, Tsuzuki D, Dan I. 2007. 10/20, 10/10, and 10/5 systems revisited: their validity as relative head-surface-based positioning systems. Neuroimage 34: 1600-1611. (Pubitemid 46187062)
34. Kapur S, Remington G. 2001. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52: 503-517. (Pubitemid 32195338)
35. Karow A, Naber D. 2002. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berlin) 162: 3-10. (Pubitemid 34639549)
36. Katz N, Tadmor I, Felzen B, Hartman-Maeir A. 2007. The Behavioural Assessment of the Dysexecutive Syndrome (BADS) in schizophrenia and its relation to functional outcomes. Neuropsychol Rehabil 17: 192-205. (Pubitemid 46594792)
37. Keefe RS, Silva SG, Perkins DO, Lieberman JA. 1999. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201-222. (Pubitemid 29272501)
38. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al. 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633-647. (Pubitemid 46878665)
39. Kerns JG, Cohen JD, MacDonald AW 3rd, Johnson MK, Stenger VA, Aizenstein H et al. 2005. Decreased confl ict-and error-related activity in the anterior cingulate cortex in subjects with schizophrenia. Am J Psychiatry 162: 1833-1839. (Pubitemid 41428612)
40. Kreukels BPC, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, van Dam FSAM. 2005. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 94: 53-61. (Pubitemid 41416942)
41. Kuroki T, Meltzer HY, Ichikawa J. 1999. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288: 774-781. (Pubitemid 29119694)
42. Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT Jr. 2001. Abnormal patterns of regional cerebral blood fl ow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 158: 1797-1808. (Pubitemid 33054772)
43. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M et al. 2004. Clozapine but not haloperidol Reestablishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 29: 171-178. (Pubitemid 38068027)
44. Laurens KR, Ngan ET, Bates AT, Kiehl KA, Liddle PF. 2003. Rostral anterior cingulate cortex dysfunction during error processing in schizophrenia. Brain 126: 610-622. (Pubitemid 36240862)
45. Lauriello J, Mathalon DH, Rosenbloom M, Sullivan EV, Faustman WO, Ringo DL et al. 1998. Association between regional brain volumes and clozapine response in schizophrenia. Biol Psychiatry 43: 879-886. (Pubitemid 28288366)
46. Lehmann D, Skrandies W. 1984. Spatial analysis of evoked potentials in man-a review. Prog Neurobiol 23: 227-250.
47. Leucht S. 2007. Psychiatric treatment guidelines: doctors ' noncompliance or insuffi cient evidence? Acta Psychiatr Scand 115: 417-419.
48. Meltzer HY, Matsubara S, Lee JC. 1989. The ratios of serotonin2 and dopamine2 affi nities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25: 390-392. (Pubitemid 20260244)
49. Moghaddam B, Bunney BS. 1990. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755-1760.
50. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. 2008. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165: 978-987.
51. Northoff G, Witzel T, Richter A, Gessner M, Schlagenhauf F, Fell J et al. 2002. GABA-ergic modulation of prefrontal spatiotemporal activation pattern during emotional processing: a combined fMRI/MEG study with placebo and lorazepam. J Cogn Neurosci 14: 348-370. (Pubitemid 34267538)
52. Pascual-Marqui RD. 2002. Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details. Methods Find Exp Clin Pharmacol 24(Suppl D): 5-12. (Pubitemid 35462350)
53. Pehek EA, Yamamoto BK. 1994. Differential effects of locally administered clozapine and haloperidol on dopamine effl ux in the rat prefrontal cortex and caudate-putamen. J Neurochem 63: 2118-2124. (Pubitemid 24369986)
54. Priebe S, Gruyters T, Heinze M, Hoffmann C. 1995. Subjektive Evaluationskriterien in der psychiatrischen Versorgung-Ergebungsmethoden f ü r Forschung und Praxis. Psychiatr Prax 22: 140-144.
55. Quintana SM, Maxwell SE. 1994. A Monte Carlo comparison of seven-adjustment procedures in repeated measures designs with small sample sizes. J Statist Educ 19: 57-71.
56. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 2000. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48: 229-237. (Pubitemid 30618995)
57. Snitz BE, MacDonald A 3rd, Cohen JD, Cho RY, Becker T, Carter CS. 2005. Lateral and medial hypofrontality in fi rstepisode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry 162: 2322-2329. (Pubitemid 41740211)
58. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY. 1993. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266: 1374-1384. (Pubitemid 24175781)
59. Vaiva G, Cottencin O, Llorca PM, Devos P, Dupont S, Mazas O, et al. 2002. Regional cerebral blood fl ow in defi cit/nondefi cit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry 26: 481-485. (Pubitemid 34252941)
60. Wacker J, Chavanon M-L, Leue A, Stemmler G. 2010. Trait BIS predicts alpha asymmetry and P300 in a Go/No-Go task. Eur J Pers 24: 85-105.
61. Weinberger DR, Lipska BK. 1995. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16: 87-110.
62. Windischberger C, Lanzenberger R, Holik A, Spindelegger C, Stein P, Moser U, et al. 2010. Area-specifi c modulation of neural activation comparing escitalopram and citalopram revealed by pharmacofMRI: a randomized cross-over study. Neuroimage 49: 1161-1170.
63. Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2005. A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472. (Pubitemid 41002500)